Bellvitge Hospital
Barcelona, 08907, Spain
NCT Number: NCT02835391
This study is a post market, multi-centre, randomised study evaluating PerClot compared to usual care. PerClot is a CE marked device and is currently used as a haemostat in gynaecological surgery throughout Europe. The purpose of this study is to collect additional post market data on its use in this indication.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Barcelona, 08907, Spain
This study is a post market, multi-centre, randomised study evaluating PerClot compared to usual care.
All subjects in this randomized study will undergo a laparoscopic or open gynecological procedure such as hysterectomy, cystectomy, myomectomy, endometrial excision or ablation. Subjects will be randomized to receive PerClot or usual care.
This research will utilize a multi-center, prospective, randomized controlled study. The study will be conducted in2 study sites in Europe. An assumed sample of 90 subjects will be enrolled to evaluate the time to haemostasis. The enrollment of subjects to receive treatment will be based upon specific inclusion and exclusion criteria. Subjects will be randomized on a 1:1 basis to receive either PerClot or usual care. Data collected from both arms will be compared.
Usual care will be at the discretion of the surgeon and may include any other haemostat or diathermy/electrocautery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
Haemostatic device for the control of bleeding
Procedure for the control of bleeding
Time frame: measured up to 10 minutes after application
visual observation of cessation of bleeding
Time frame: within 30 days of initial surgery
No return to OR for bleeding
Time frame: within 30 days of initial surgery
No positive culture of blood results which indicate infection
Time frame: within 30 days of initial surgery
No adverse events which are specifically caused by bleeding
CryoLife Europa
Industry
A Prospective, Multi-Centre, Randomized, Safety and Effectiveness Study of PerClot Compared to Usual Care When Used During Gynaecology Procedures
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01793584
Adenomyosis, Adnexal Diseases
Dallas, Texas, United States
View Trial DetailsNCT07664956
Abnormal Uterine Bleeding, Unspecified, Adenomyosis
Newark, Delaware, United States
View Trial DetailsNCT06949124
Assisted Reproduction, Endometriosis
Wuhan, Hubei, China
View Trial DetailsNCT06969664
Assisted Reproduction, Endometriosis
Guangzhou, Guangdong, China
View Trial Details